Audit: QRS - Gamma-Hydroxybutyrate for Health & Longevity

Audit conducted on 14/08/2026 12:00 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every protocol value (4.5 g nightly, 1.5 g titration to 9 g, 2.5–4 h second dose, 5–15 min onset, two-hour food window), every biomarker target, every gate item and every tiered benefit/risk traces to a literal ER passage.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“unstudied consequences of decades-long exposure” (ER line 339), “No established target; track change from own baseline” (ER line 523) and “Nothing is known about decades of nightly use” (ER line 557) all mirror the ER’s hedging.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Absolute contraindications stay in the Contraindications gate (alcohol, opioids, benzodiazepines, industrial precursors); caution-level interactions stay in Key Interactions. No tier migration in either direction.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Benefits come only from Expected Benefits, risks only from Potential Risks & Side Effects, gates only from Key Interactions & Contraindications; no Benefit- or Risk-Modifying Factor bullet appears anywhere in the QRS.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, author names, NCT identifiers, or brand names (Xyrem/Xywav/Lumryz/Jazz) at all.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Flat, declarative, non-promotional register matching the ER; the narrow therapeutic-margin framing of the ER Conclusion is carried into At-A-Glance.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and dosing alongside plain-language explanations of why each marker matters.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol cells describe the licensed regimen rather than instructing; no imperative voice in any populated span.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Monitoring targets are stated as ranges, not instructions; contraindications are stated as populations/conditions, not directives.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise”, “should”, or “must” in any populated span.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns in any data-qrs-var span.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	“Sleepwalking and confusional arousals”, “night-time bedwetting”, “widespread chronic pain” are used in place of the ER’s heavier headings; residual technical terms (ALDH5A1, Child-Pugh, NYHA) are load-bearing decision criteria.
2.8	Information is presented in a concise and very compact manner	🟢	Tiered benefits and risks are semicolon-joined single lines; gate items are noun phrases; the whole sheet is one continuous compact card stack.
2.9	It DOES NOT address the reader directly	🟢	Confirmed across all 74 populated spans.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Monitoring panel uses the ER’s tighter-than-conventional functional targets (sodium 138–142, eGFR >90, Epworth 0–5), which only a proactive optimiser would act on.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Retains the mid-night second dose, the two-hour food-free window, the overnight breathing study and the 11-marker panel without softening the burden.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Density and specificity of the monitoring cadence and gate list are well beyond general-population material.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Time-to-effect leads with sleep architecture, the ER’s explicitly “most relevant to a longevity-oriented reader” effect, while At-A-Glance foregrounds the narrow respiratory margin and the absent long-horizon data.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” appears in the title and header; “anti-aging” appears nowhere.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Night-time bedwetting”, “confusional arousals” and “morning grogginess” are the ER’s own terms (ER lines 527–533); no consumer-grade substitutions were introduced by the QRS.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All verified verbatim: lines 443, 484, 528, 610, 643, 811 (headings), 562, 585 (gates), 532/539/545/552 and 614/620/628/634 (tiers), 647–649 (table headers).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	74 named spans present with no gaps in any numbered series (action 1–3, time 1–3, marker 1–11, qualitative 1–7) and all four benefit and risk tiers plus both gate spans.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The three non-data-qrs-var template spans (website="evidence_review", website="full_review", website="audit") are untouched at lines 421, 424, 437; footer disclaimer and CSS block are unmodified.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty; every benefit tier, risk tier, gate and monitoring row has ER content.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard licensed regimen”, “Timing” and “Food separation” match the ER Protocol bold labels at lines 418, 428 and 434 exactly.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect labels (“Sleep architecture”, “Cataplexy and daytime sleepiness”, “Fibromyalgia pain”) are lifted verbatim from the ER’s Time to effect bullet (line 479); all 11 marker names match the ER biomarker table column 1.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Zero tier emoji in the file; the ER’s “⚠️ Conflicted” markers on alcohol abstinence and sleep-disordered breathing were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every item is already reduced to its minimum: gate entries are bare noun phrases, tier lines are semicolon-joined, and monitoring “Why” cells are single clauses. Further reduction would require dropping items that 8.2 and 14.2 mandate be present.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14; <html> opens at line 15.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preamble text on line 2 sits before the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the header, footer, or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly so because it contains a colon; all other values are bare and untrimmed of nothing.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: gamma_hydroxybutyrate_2026-0814-0900_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0814-1144.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the actual filename gamma_hydroxybutyrate_2026-0814-0900_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; git_user: evipedia-3 and git_issue: 5144 are bare and correctly unquoted.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 20: “Gamma-Hydroxybutyrate for Health & Longevity - Quick Reference Sheet”; ampersand correctly encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 415: “Gamma-Hydroxybutyrate for Health & Longevity”, matching ER frontmatter line 8.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 419: “08/14/2026” from qrs_creation_date: 2026-0814-1144.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 423: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template subline; the ER’s “Also known as” list (ER line 30) was correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses ER lines 555–559: the single mechanism, the three demonstrated effects, the narrow respiratory margin, and the absent long-term record.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“prescription-only” ← ER line 464; “forces the brain into its deepest sleep, then clears fast” ← line 555; “rare sleep disorder” / “widespread chronic pain” / “growth hormone pulse” ← line 555; “gap … is narrow” ← line 559; “Nothing is known about decades of nightly use” ← line 557.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “narcolepsy” rendered as “a rare sleep disorder” and “fibromyalgia” as “widespread chronic pain”.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial, author, year, or sample size appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind in the span.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All 11 items map to ER lines 363–394.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All 10 bullets of the ER “Populations who should avoid” list are present, plus “Industrial precursors”, which ER line 379 labels an absolute contraindication.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	11 <li> elements inside the span (lines 565–580).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing “— absolute” (line 385) is stripped; the only en-dash remaining is inside the range “NYHA Class III–IV”, not a trailing clause.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“AHI ≥15 events per hour”, “Child-Pugh Class C … Class B without halved dosing”, “NYHA Class III–IV”, “above 1 unit daily”, “under 7 years” and “(sodium-based formulations)” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication bullets use no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The section is populated, and the ER identifies many such populations, so the constraint is satisfied.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not left empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All 7 items map to ER lines 369–381.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	The five ER caution bullets are carried and the sixth (“Other interventions”) is correctly split into CPAP omission and evening sauna; the four absolute-contraindication bullets (alcohol, benzodiazepines/Z-drugs, opioids, industrial precursors) are excluded and sit in the Contraindications gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	7 <li> elements inside the span (lines 588–600).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s mechanistic tails (e.g. “Valproate raises oxybate exposure by roughly 25% …”, line 369) are stripped; no dashes remain in any item.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All three ER example-drug lists are preserved intact: OTC sedatives (diphenhydramine, doxylamine, promethazine, dextromethorphan), muscle relaxants (baclofen, tizanidine, cyclobenzaprine) and sedating supplements (melatonin, valerian, kava, passionflower, high-dose magnesium glycinate, cannabidiol, ashwagandha).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction bullets use no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The section is populated, and the ER identifies multiple caution-level interactions, so the constraint is satisfied.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not left empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells map to ER Therapeutic Protocol bullets at lines 418, 428 and 434.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose and titration, dose timing, and the food-separation window — the three levers the ER’s own Risk Mitigation section (lines 401, 405, 407) also identifies as decisive.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Protocol section contains 15 bullets, well above three, so no set is unused.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated: labels at lines 447/460/471, values at 450/463/474, subs at 453/466/477.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Sleep architecture, cataplexy/daytime sleepiness, and fibromyalgia pain — exactly the three horizons named in the ER’s Time to effect bullet (line 479).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	All three attach to High-tier benefits; sleep-architecture consolidation leads because the ER designates it “the effect most relevant to a longevity-oriented reader” (line 166), which is the audience 2.10 defines.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides three distinct time-to-effect aspects, so no set is unused.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated; values “First night”, “One to eight weeks” and “Eight to fourteen weeks” match ER line 479 exactly.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information (line 479), so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All 13 entries map one-to-one onto the ER’s H4 benefit headings at lines 152–233.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 530, 537, 543 and 550.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a semicolon-joined list of bare benefit names; none of the ER’s Magnitude paragraphs (MWT +4.66 min, −5.04 attacks/week, 42.0%/51.4% responders) is carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits span; the ER’s “⚠️ Conflicted” flag on alcohol abstinence is also dropped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items (4 high, 3 medium, 4 low, 2 speculative), so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All 13 entries map one-to-one onto the ER’s H4 risk headings at lines 260–341.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 612, 618, 626 and 632.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a semicolon-joined list of bare risk names; the ER’s Magnitude figures (RR 6.08, ~1,640 mg sodium, 3 of 42 desaturating) are absent.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks span; the ER’s “⚠️ Conflicted” flag on sleep-disordered breathing is dropped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items (3 high, 6 medium, 2 low, 2 speculative), so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table rows and cadence both trace to the ER Monitoring Protocol & Defining Success section, lines 507–523.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 11 ER biomarker table rows are present with targets and rationale reproduced verbatim: AHI, serum sodium, home blood pressure, serum bicarbonate, eGFR, overnight oxygen saturation nadir, Epworth, PHQ-9, body weight, IGF-1, slow-wave sleep duration.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 800 reproduces ER line 509 in full: 1/4/12 weeks during escalation, then 6-monthly; sodium, bicarbonate and kidney function each stable-phase review; blood pressure monthly; mood quarterly; breathing study annually or after 5 kg gain.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All seven items map to the ER’s qualitative marker list at lines 527–533.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All seven present: morning grogginess, sleep restorativeness, confusional arousals/sleepwalking/bedwetting frequency, steadiness at second dose, daytime cognitive clarity, late-afternoon mood, post-dose nausea.

Issues 14/08/2026 12:00

Pass rate 100.00%. No issues found.

Issues 14/08/2026 11:52

1. 4.2 — ER bold label dropped for precursors: The precursor contraindication at QRS line 571 reads “Gamma-butyrolactone or 1,4-butanediol” rather than the ER’s bold label “Industrial precursors (gamma-butyrolactone, 1,4-butanediol)” (ER line 379), whereas every other interaction-derived gate item carries its ER label verbatim.
2. 4.3 — Monitoring row label abbreviated: [marker_3_name] at QRS line 679 abbreviates the ER row label “Home blood pressure (seated, morning average)” (ER line 515) to “Home blood pressure, morning average”, dropping the seated measurement condition.

Fixes 14/08/2026 11:52

1. 4.2 — Restored ER label for precursors: The precursor contraindication was changed from “Gamma-butyrolactone or 1,4-butanediol” to the ER’s bold label “Industrial precursors (gamma-butyrolactone, 1,4-butanediol)”.
2. 4.3 — Restored blood-pressure row label: [marker_3_name] was changed from “Home blood pressure, morning average” to the ER’s row label “Home blood pressure (seated, morning average)”, reinstating the seated measurement condition.